StreetInsider.com Pre-Open Movers 01/28: (KERX) (FURX) (NTE) Higher; (SCHS) (JOSB) (AKS) Lower (more...)
Tweet
Share
E-mail
School Specialty, Inc. (Nasdaq: SCHS) 61% LOWER; announced that it has entered into an asset purchase agreement with an affiliate of Bayside Capital, Inc., under which School Specialty proposes to sell its assets as a going concern through a court-supervised sale process. To facilitate the sale transaction, School Specialty and certain of its subsidiaries today filed voluntary petitions for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware and is pursuing the sale process under Section 363 of the Bankruptcy Code
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) 49% HIGHER; announced successful top-line results from the long-term Phase 3 study of Zerenex (ferric citrate), the Company's ferric iron-based phosphate binder drug candidate, for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis. In this study, Zerenex met the study's primary endpoint, described below, demonstrating a highly statistically significant change in serum phosphorus versus placebo over the four-week Efficacy Assessment Period of the study. In addition, Zerenex met the key secondary endpoints of increasing ferritin and transferrin saturation (TSAT) and reducing the use of intravenous (IV) iron and erythropoiesis-stimulating agents (ESAs) versus the active control over the 52-week Safety Assessment Period of the study.
uriex Pharmaceuticals, Inc. (NASDAQ: FURX) 47% HIGHER; confirmed that Takeda Pharmaceutical Company Limited has received approval from the U.S. Food and Drug Administration of three new type 2 diabetes therapies, NESINA (alogliptin) and the fixed-dose combination therapies, OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl), for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.
JOS A Bank Clothiers, Inc. (NASDAQ: JOSB) 18% LOWER; et income for fiscal year 2012 is expected to be approximately 20% lower than net income for fiscal year 2011.
Nam Tai Electronics, Inc. (NYSE: NTE) 15% HIGHER;reported Q4 EPS of $0.82, versus ($0.13) reported last year. Revenue for the quarter came in at $468.46 million, versus $129.07 million reported last year.
Immunomedics, Inc. (Nasdaq: IMMU) 6% HIGHER; announced an agreement with Algeta ASA (OSE: ALGETA) for the development of Immunomedics' humanized anti-CD22 antibody, epratuzumab, conjugated with Algeta's proprietary thorium-227 alpha-pharmaceutical payload.
Dole Food Company Inc. (Nasdaq: DOLE) 6% HIGHER; positive Barron's mention
Hess Corp. (NYSE: HES) 6% HIGHER; will pursue the sale of its terminal network in the United States. Hess also announced that it will complete its exit from the refining business by closing its Port Reading, New Jersey refinery.
AK Steel (NYSE: AKS) 4% LOWER; downgraded at Goldman Sachs
Century Aluminum Co. (NASDAQ: CENX) 4% LOWER; downgraded at Goldman Sachs
Bed Bath & Beyond Inc. (NASDAQ: BBBY) 3% LOWER; downgraded at Goldman Sachs
Best Buy Co., Inc. (NYSE: BBY) 3% HIGHER; Upgraded at BB&T
ASML Holding NV (NASDAQ: ASML) 3% HIGHER; Upgraded at Citi
Chipotle Mexican Grill, Inc. (NYSE: CMG) 3% HIGHER; Upgraded at Lazard
Caterpillar, Inc. (NYSE: CAT) 2% HIGHER; reported Q4 EPS of $1.91, $0.20 better than the analyst estimate of $1.71. Revenue for the quarter came in at $16.08 billion versus the consensus estimate of $16.16 billion. Caterpillar, Inc. sees FY2013 EPS of $7.00-9.00, versus the consensus of $8.54. Caterpillar, Inc. sees FY2013 revenue of $60-68 billion, versus the consensus of $65.18 billion
Transocean Ltd. (NYSE: RIG) 2% HIGHER; Carl Icahn raises stake, wants $4/sh dividend
News Corp. (NASDAQ: NWSA) 2% HIGHER; upgraded at Morgan Stanley
Xerox Corp. (NYSE: XRX) 2% HIGHER; upgraded at BMO
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) 49% HIGHER; announced successful top-line results from the long-term Phase 3 study of Zerenex (ferric citrate), the Company's ferric iron-based phosphate binder drug candidate, for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis. In this study, Zerenex met the study's primary endpoint, described below, demonstrating a highly statistically significant change in serum phosphorus versus placebo over the four-week Efficacy Assessment Period of the study. In addition, Zerenex met the key secondary endpoints of increasing ferritin and transferrin saturation (TSAT) and reducing the use of intravenous (IV) iron and erythropoiesis-stimulating agents (ESAs) versus the active control over the 52-week Safety Assessment Period of the study.
uriex Pharmaceuticals, Inc. (NASDAQ: FURX) 47% HIGHER; confirmed that Takeda Pharmaceutical Company Limited has received approval from the U.S. Food and Drug Administration of three new type 2 diabetes therapies, NESINA (alogliptin) and the fixed-dose combination therapies, OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl), for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.
JOS A Bank Clothiers, Inc. (NASDAQ: JOSB) 18% LOWER; et income for fiscal year 2012 is expected to be approximately 20% lower than net income for fiscal year 2011.
Nam Tai Electronics, Inc. (NYSE: NTE) 15% HIGHER;reported Q4 EPS of $0.82, versus ($0.13) reported last year. Revenue for the quarter came in at $468.46 million, versus $129.07 million reported last year.
Immunomedics, Inc. (Nasdaq: IMMU) 6% HIGHER; announced an agreement with Algeta ASA (OSE: ALGETA) for the development of Immunomedics' humanized anti-CD22 antibody, epratuzumab, conjugated with Algeta's proprietary thorium-227 alpha-pharmaceutical payload.
Dole Food Company Inc. (Nasdaq: DOLE) 6% HIGHER; positive Barron's mention
Hess Corp. (NYSE: HES) 6% HIGHER; will pursue the sale of its terminal network in the United States. Hess also announced that it will complete its exit from the refining business by closing its Port Reading, New Jersey refinery.
AK Steel (NYSE: AKS) 4% LOWER; downgraded at Goldman Sachs
Century Aluminum Co. (NASDAQ: CENX) 4% LOWER; downgraded at Goldman Sachs
Bed Bath & Beyond Inc. (NASDAQ: BBBY) 3% LOWER; downgraded at Goldman Sachs
Best Buy Co., Inc. (NYSE: BBY) 3% HIGHER; Upgraded at BB&T
ASML Holding NV (NASDAQ: ASML) 3% HIGHER; Upgraded at Citi
Chipotle Mexican Grill, Inc. (NYSE: CMG) 3% HIGHER; Upgraded at Lazard
Caterpillar, Inc. (NYSE: CAT) 2% HIGHER; reported Q4 EPS of $1.91, $0.20 better than the analyst estimate of $1.71. Revenue for the quarter came in at $16.08 billion versus the consensus estimate of $16.16 billion. Caterpillar, Inc. sees FY2013 EPS of $7.00-9.00, versus the consensus of $8.54. Caterpillar, Inc. sees FY2013 revenue of $60-68 billion, versus the consensus of $65.18 billion
Transocean Ltd. (NYSE: RIG) 2% HIGHER; Carl Icahn raises stake, wants $4/sh dividend
News Corp. (NASDAQ: NWSA) 2% HIGHER; upgraded at Morgan Stanley
Xerox Corp. (NYSE: XRX) 2% HIGHER; upgraded at BMO
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rubrik IPO: 5 key things to know
- Complete Solaria (CSLR) Issues Update on Operational Progress & PE Debt
- Red Lobster Mulls Filing For Bankruptcy To Fix Balance Sheet - Bloomberg
Create E-mail Alert Related Categories
Special ReportsRelated Entities
Carl Icahn, Citi, Morgan Stanley, Lazard, Barron's, BB&T Capital Markets, Dividend, BankruptcySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
